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I. INTRODUCTION 
Since Congress amended the False Claims Act (FCA) in 1986, the stat-
ute has evolved into a seemingly boundless weapon for enforcing other stat-
utes and regulations applicable to every industry that accepts any form of gov-
ernment funding. Use of the FCA by the Department of Justice (DOJ) and by 
private citizens bringing actions on behalf of the U.S. government to enforce 
other statutes and regulations is particularly evident in the field of health 
care.1 The FCA has been utilized in actions where the allegations include off-
label promotion of drugs, kickbacks, and violations of current good manufac-
turing practices (cGMPs) by linking the alleged violation with the government 
reimbursement under Medicare and Medicaid. cGMP violations, however, are 
historically enforced by the Food and Drug Administration (FDA) under the 
Food, Drug, and Cosmetic Act (FDCA), which regulates the safety and ef-
fectiveness of drugs and devices. Whether alleged cGMP violations are sub-
ject to enforcement by the FDA under the FDCA or by the DOJ and private 
citizens on behalf of the United States government under the FCA, or both, 
has been heavily debated recently.2 
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 1. See John T. Brennan, Jr. & Michael W. Paddock, Limitations on the Use of the False Claims 
Act to Enforce Quality of Care Standards, 2 J. HEALTH & LIFE SCI. L. 37, 40 (2008). 
 2. Heather Banuelos, More Scrutiny for cGMP Violations, CONTRACT PHARMA (May 6, 2013), 
http://www.contractpharma.com/issues/2013-05/view_fda-watch/more-scrutiny-for-cgmp-
violations/. 
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The DOJ successfully used the FCA as the statutory hook to enable its 
enforcement authority in an action against GlaxoSmithKline (GSK)3 and 
Ranbaxy USA, Inc.4 DOJ alleged that both companies released adulterated 
drugs into the stream of commerce in violation of FDCA cGMPs.5 The action 
against GSK resulted in a $750 million settlement with the United States At-
torney’s Office for the District of Massachusetts;6 Ranbaxy settled with the 
District of Maryland for $500 million.7 These enforcement actions seem to 
indicate that the FCA may be used to enforce FDCA cGMP, quality sys-
tem regulation (QSR) violations, or both.8 However, in February 2014, 
the Fourth Circuit in United States ex rel. Rostholder v. Omnicare, Inc. 
seemingly put the brakes on DOJ’s ability to invoke the FCA to enforce 
cGMP violations when the court held that “adulterated drugs are not 
barred from reimbursement by Medicare and Medicaid and, therefore, 
claims for reimbursement for these drugs cannot be ‘false’ under the 
FCA.”9 While the Rostholder decision may indicate that using the FCA to 
enforce the FDCA—and cGMP violations specifically—may not be the fer-
tile ground for sweeping DOJ enforcement as originally imagined; the deci-
sion may have simply clarified that the DOJ’s enforcement reach is limited to 
fraud on the FDA, which may include underlying cGMP violations. 
This Article examines the statutory background of cGMPs and 
QSRs, considers enforcement of cGMP violations by both the FDA un-
der the FDCA and the DOJ under the FCA, and proposes that fraudulent 
and felonious violations of cGMPs should be enforced by the DOJ under 
the FCA because DOJ has the resources and the expertise to investigate 
and prosecute such violations. Non-fraudulent cGMP violations, on the 
                                                 
 3. See generally Settlement Agreement, United States ex rel. Eckard v. GlaxoSmithKline,  No. 
10-cv-10375 (D. Mass. Oct. 26, 2010), 2010 WL 4339999 [hereinafter GSK Settlement Agreement] 
(agreeing, in part, to release GSK from potential FCA liability).  
 4. See generally Settlement Agreement, United States ex rel. Thakur v. Ranbaxy Labs., Ltd.  
No. JFM-07-962 (D. Md. May 13, 2013) [hereinafter Ranbaxy Settlement Agreement], available at 
http://www.justice.gov/iso/opa/resources/692013513142957691677.pdf (agreeing, in part, to release 
Ranbaxy Laboratories, Ltd. from potential FCA liability). 
 5. See GSK Settlement Agreement, supra note 3; Ranbaxy Settlement Agreement, supra note 
4. 
 6. GlaxoSmithKline to Plead Guilty & Pay $750 Million to Resolve Criminal and Civil Liabil-
ity Regarding Manufacturing Deficiencies at Puerto Rico Plant, U.S. DEP’T OF JUSTICE (Oct. 26, 
2010), http://www.justice.gov/opa/pr/2010/October/10-civ-1205.html. 
 7. Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Re-
solve False Claims Allegations, cGMP Violations and False Statements to the FDA, U.S. DEP’T OF 
JUSTICE (May 13, 2013), http://www.justice.gov/opa/pr/2013/May/13-civ-542.html. 
 8. See generally GSK Settlement Agreement, supra note 3; Ranbaxy Settlement Agreement, 
supra note 4. See also Consent Decree of Permanent Injunction, United States v. McNeil–PPC, Inc., 
No. 11-1745 (E.D. Pa. March 10, 2011) [hereinafter McNeil–PPC, Inc. Consent Decree], available 
at http://media.npr.org/assets/blogs/health/images/2011/03/mcneilconsentdecree.pdf. 
 9. United States ex rel. Rostholder v. Omnicare, Inc., 745 F.3d 694, 703 (4th Cir. 2014). 
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other hand, should be enforced by the FDA under the FDCA because the 
FDA has both the subject matter expertise and the statutory mandate to 
regulate drugs and medical devices. 
II. STATUTORY BACKGROUND OF CGMPS AND QSRS 
The government heavily regulates the manufacturing of drugs and 
medical devices. Under the FDCA, the Secretary of Health and Human 
Services may 
prescribe regulations requiring that the methods used in, and the fa-
cilities and controls used for, the manufacture . . . of a device con-
form to current good manufacturing practice, as prescribed in such 
regulations, to assure that the device will be safe and effective and 
otherwise in compliance with this [Act].10 
Consistent with this statutory mandate, the Secretary has created a 
“quality system regulation,” or “QSR,” that sets forth current good man-
ufacturing practice requirements, commonly referred to as cGMPs.11 The 
FDA has statutory authority to enforce violations of the FDCA. 
A. Setting QSR and cGMP Standards 
QSRs “govern the methods used in, and the facilities and controls 
used for, the . . . manufacture . . . of all finished devices intended for hu-
man use,” and are “intended to ensure that finished devices will be safe 
and effective and otherwise in compliance with the [FDCA].”12 These 
regulations require manufacturers to establish specifications and controls 
for quality and safety.13 The FDA’s Medical Device Quality Systems 
Manual specifies: 
[cGMPs] require that domestic or foreign manufacturers have a 
quality system for the design and production of medical devices in-
tended for commercial distribution in the United States. The regula-
tion requires that various specifications and controls be established 
for devices; that devices be designed under a quality system to meet 
these specifications; that devices be manufactured under a quality 
system; that finished devices meet these specifications; that devices 
be correctly installed, checked and serviced; that quality data be an-
                                                 
 10. 21 U.S.C. § 360j(f)(1)(A) (2012). 
 11. See 21 C.F.R. §§ 820.1(a)(1), (c) (2010). 
 12. 21 C.F.R. § 820.1(a)(1) (2010). 
 13. See 21 C.F.R. §§ 820.20–820.75 (2014). 
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alyzed to identify and correct quality problems; and that complaints 
be processed.14 
The regulations are flexible, however. The FDA notes that “‘[e]ach 
manufacturer shall establish and maintain a quality system that is appro-
priate for the specific device(s) designed or manufactured, and that meets 
the requirements of this part.’ The word ‘appropriate’ means that the rule 
is a flexible regulation.”15 The FDA explains: 
FDA has identified in the QS regulation the essential elements that a 
quality system shall embody for design, production and distribution, 
without prescribing specific ways to establish these elements. Be-
cause the QS regulation covers a broad spectrum of devices and 
production processes, it allows some leeway in the details of quality 
system elements. It is left to manufacturers to determine the necessi-
ty for, or extent of some quality elements and to develop and im-
plement specific procedures tailored to their particular processes 
and devices.16 
It is not practical for the FDA to delineate quality system elements 
for each of the numerous devices on the market. Instead, general objec-
tives are specified and manufacturers are left to determine the best meth-
ods to attain quality objectives.17 
The FDA also requires that drug makers’ manufacturing facilities 
comply with cGMPs, which establish the minimum requirements for the 
methods, facilities, and controls used in manufacturing and processing 
human drugs in order to prevent the production of unsafe and ineffective 
products.18 To ensure compliance, the agency conducts inspections peri-
odically and in conjunction with drug applications. Compliance with the 
cGMP requirements assures that drugs and devices meet the safety re-
quirements of the FDCA and have the quality, purity, identity, and 
strength characteristics that they purport or are represented to possess. 
Drugs and devices not manufactured, processed, packaged, or held in 
conformance with cGMP requirements are deemed adulterated within the 
meaning of 21 U.S.C. § 351(a)(2)(B).19 
                                                 
 14. ANDREW LOWERY ET AL., U.S. FOOD & DRUG ADMIN., MEDICAL DEVICE QUALITY 
SYSTEMS MANUAL: A SMALL ENTITY COMPLIANCE GUIDE at 1-1 (1st ed. 1996), available at 
http://www.gmp-compliance.org/guidemgr/files/MDQS.manual.pdf. 
 15. Id. at 1-2 (quoting 21 C.F.R. at § 820.5). 
 16. Id. 
 17. Id. 
 18. See 21 C.F.R. §§ 210–11 (2011). 
 19. 21 U.S.C. § 351(a)(2)(B) (2012). 
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Because the FDCA does not provide a definition of what constitutes 
cGMPs, the determination of what constitutes cGMPs is often a matter of 
judgment and interpretation20 The FDA uses the concept of “current” 
GMP to continuously advance industry best practices and to advance 
practices not yet used in the industry but that the FDA determines could 
improve manufacturing controls and drug or device product integrity.20 
As a result, the FDA establishes cGMP requirements informally via 
speeches, guidance documents, FDA investigators’ inspection observa-
tions, and letters to manufacturers.21 A violation may “result from a good 
faith technical dispute about what cGMP requires in a particular set-
ting.”22 Theoretically, a conclusion by a field investigator that a particu-
lar practice violates cGMP may reflect nothing more than miscommuni-
cation between the agency and industry.23 
Significantly, as noted, failure to comply with the QSR “renders a 
device adulterated under section 501(h)” of the FDCA, and “[s]uch a 
device, as well as any person responsible for the failure to comply, is 
subject to regulatory action.”24 Under 21 U.S.C. § 351(a)(2)(B), a drug is 
adulterated if: 
[T]he methods used in, or the facilities or controls used for, its 
manufacture, processing, packing, or holding do not conform to or 
are not operated or administered in conformity with current good 
manufacturing practice to assure that such drug meets the require-
ments of this chapter as to safety and has the identity and strength, 
and meets the quality and purity characteristics, which it purports or 
is represented to possess . . . .25 
Once the FDA deems a drug or device adulterated, the FDA has 
several enforcement tools in its arsenal to remedy the manufacturing 
failure and to protect consumers from exposure to the drug. 
B. FDA’s cGMP Violation Enforcement Tools 
The FDA is responsible for investigating violations of the FDCA, 
including those related to adulterated drugs and devices.26 The Agency 
may exercise its enforcement authority, derived from 21 U.S.C. § 331, 
                                                 
 20. Id. at 154. 
 21. Id. 
 22. Id. 
 23. Id. 
 24. 21 C.F.R. § 820.1(c) (2010). 
 25. 21 U.S.C. § 351(a)(2)(B) (2012). 
 26. See 21 U.S.C. § 372(a)(1) (2009) (authorizing the Secretary of Health and Human Services 
“to conduct examinations and investigations for the purpose of [the FDCA]”). 
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when a prohibited act has been identified. Prohibited acts include inter-
state shipment of adulterated drugs and devices, and selling devices not 
made in conformance with QSR or cGMP requirements.27 The FDA has 
three primary enforcement tools available to combat FDCA violations. 
These tools include advisory actions, such as letters; administrative ac-
tions, such as recalls and civil penalties; and judicial actions, such as sei-
zures, injunctions, and criminal prosecutions.28 In addition, the FDA re-
lies on voluntary compliance and informal enforcement mechanisms. 
1. Advisory Actions 
Although the FDA may undertake formal regulatory action in order 
to enforce its statute,29 in practice the FDA tends to follow a more infor-
mal path when pursuing corporate compliance with its statute, which in-
cludes issuing informal advisory actions. For example, if an FDA inspec-
tor finds “significant objectionable conditions,” during an on-site inspec-
tion, the FDA will typically issue a Form 483, which lists “inspectional 
observations”30 but does not constitute a finding of cGMP violations.31 
The Form 483 is informal and advisory in nature, and is issued with the 
expectation that most firms will voluntarily comply with the law by ame-
liorating the deficiencies observed.32 Should the drug or device maker 
not promptly address those observations—or if the FDA finds a more 
serious violation—the FDA may issue a Warning Letter.33 The Warning 
Letter constitutes an FDA finding of cGMP noncompliance and puts the 
                                                 
 27. 21 U.S.C § 331(a) (2013). 
 28. See Nancy Mathewson, Prohibited Acts and Enforcement Tools, 65 FOOD & DRUG L.J. 
545, 546 (2010). 
 29. See 21 U.S.C. § 332 (2014); 21 U.S.C. § 333(f)(1)(A) (2012); 21 U.S.C. § 334(a)(2)(D) 
(2012). See also U.S. FOOD & DRUG ADMIN. OFFICE OF REGULATORY AFFAIRS, REGULATORY 
PROCEDURES MANUAL ch. 4 (2012), available at http://www.fda.gov/iceci/compliancemanuals/ 
regulatoryproceduresmanual/default.htm [hereinafter FDA MANUAL]. However, the FDA is required 
to provide written notification when it discovers that products fail to comply with a performance 
standard or contain impermissible radioactivity. Id. 
30. U.S. FOOD & DRUG ADMIN., Inspection Procedures, in INVESTIGATIONS OPERATIONS 
MANUAL at ch. 5.2 (2014), available at http://www.fda.gov/iceci/inspections/iom/ucm122530.htm 
 31. See id.; see also 21 U.S.C. § 374(b) (2012). 
 32. FDA MANUAL, supra note 30, at § 4-1-1. 
 33. The FDA issues a Warning Letter to the highest known company official, which includes: 
(1) the title “WARNING LETTER”; (2) the inspection dates (if applicable); (3) a description of the 
violative condition, practice, or product, including the section of law and/or regulation violated; (4) 
acknowledgement of any corrections promised during an inspection; (5) a request for correction and 
a written response within a specific period of time after the date of the receipt of the letter (usually 
fifteen working days); (6) a warning statement that failure to correct the violative condition(s) may 
result in enforcement action without further notice; and (7) notice that other federal agencies will be 
advised of the Warning Letter. See FDA MANUAL, supra note 30, at ch. 4. 
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manufacturer on notice that an enforcement or regulatory action could be 
forthcoming if the violations are not promptly remedied.34 
2. Administrative Actions 
If the FDA determines that a device is adulterated, the agency may 
order that the device be detained for up to twenty to thirty days if neces-
sary to institute a judicial enforcement action, such as a product seizure 
or an injunction.35 The FDA may also choose to request a product re-
call.36 Typically, the FDA will issue a recall when the Agency believes 
that there is a grave public health issue at stake.37 
The FDA may elect to institute an administrative proceeding 
against a drug or device company seeking civil monetary penalties.38 The 
FDA holds subpoena power, which includes the ability to require attend-
ance of witnesses and the production of evidence relating to the matter 
being investigated.39 After notice and an opportunity for a full adminis-
trative hearing,40 the FDA may impose civil monetary penalties for sig-
nificant QSR violations ranging from $15,000 per violation up to a max-
imum of $1,000,000 in a given proceeding.41 
3. Judicial Enforcement 
Enforcement actions include seizure, injunctive relief (consent de-
crees), and imposition of civil penalties. A drug or device may be seized 
under 21 U.S.C. § 334(a)(2)(D), which states that any adulterated or 
misbranded device “shall be liable to be proceeded against at any time on 
libel of information and condemned in any district court of the United 
States or United States court of a Territory within the jurisdiction of 
which they are found.”42 
A statutory injunction proceeding is brought under the FDCA, 21 
U.S.C. § 332(a), to permanently enjoin a company from: (a) violating 21 
U.S.C. § 331(a) by introducing or delivering, or causing to be introduced 
or delivered, into interstate commerce drugs that are adulterated within 
the meaning of 21 U.S.C. § 351(a)(2)(B); (b) violating 21 U.S.C. § 
331(k) by causing drugs that defendants hold for sale after shipment of 
                                                 
 34. FDA MANUAL, supra note 30, at §§ 4-1, 4-1-10. 
 35. 21 U.S.C. § 334(g)(1) (2012). 
 36. 21 C.F.R. § 7.40 (2010). 
 37. Id. 
 38. See 21 U.S.C. § 333(f) (2012). 
 39. See Mathewson, supra note 29, at 548; see also 21 C.F.R. § 17 (2009). 
 40. See 21 C.F.R. §§ 17.13, 17.33(a) (2009).  
 41. 21 U.S.C. § 333(b)(7) (2012); see also 21 C.F.R. § 17.2 (2014). 
 42. 21 U.S.C. § 334(a)(2)(D) (2012). 
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one or more of their components in interstate commerce to become adul-
terated within the meaning of 21 U.S.C. § 351(a)(2)(B); or (c) violating 
21 U.S.C. § 331(a) by introducing or delivering, or causing to be intro-
duced or delivered, into interstate commerce drugs that are adulterated 
within the meaning of 21 U.S.C. § 351(c). 
Civil liability under 21 U.S.C. § 333(f)(1)(A) is conferred upon 
“any person who violates a requirement of [the FDCA] which relates to 
devices . . . for a civil penalty in an amount not to exceed $15,000 for 
each such violation, and not to exceed $1,000,000 for all such violations 
adjudicated in a single proceeding.”43 
4. Voluntary Compliance and Other Enforcement Mechanisms 
The FDA has additional options short of invoking an administrative 
proceeding or seeking judicial intervention that assist the Agency in its 
enforcement efforts. For example, if the FDA determines that a device 
presents an unreasonable risk of substantial harm, the agency may issue 
notification orders, which order a party to notify all healthcare profes-
sionals of the unreasonable risk identified.44 Should a firm choose not to 
comply with the FDA’s notification order, the FDA may issue its own 
safety alert or warning.45 Through publicity, the FDA may pressure a 
firm to voluntarily recall its product.46 The FDA may also issue a pre-
market approval suspension or withdrawal if evidence exists that a de-
vice is unsafe or ineffective or does not conform to GMP regulation re-
quirements.47 If the FDA determines that a device presents an unreasona-
ble risk of illness or injury, the agency may institute proceedings to ban 
the device.48 
Finally, while the FDA recommends that component manufacturers 
voluntarily follow the QSR and cGMP, it does not specify how to do so 
with any level of granularity. The FDA itself views the QSR as providing 
broad flexibility to device manufacturers. Because the regulation must 
apply to so many different types of devices, the regulation does not pre-
scribe in detail how a manufacturer must produce a specific device. Ra-
ther, the regulation provides the framework that all manufacturers must 
follow by requiring that manufacturers develop and follow procedures 
                                                 
 43. 21 U.S.C. § 333(f)(1)(A) (2012). 
 44. 21 U.S.C. § 360(h)(a) (2012). 
 45. See Mathewson, supra note 29, at 551; see generally Medical Device Safety Communica-
tions, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ 
default.htm (last visited Aug. 24, 2014). 
 46. See 21 C.F.R. § 7 (2009). 
 47. 21 U.S.C. § 360(e) (2012). 
 48. 21 U.S.C. § 360(f) (2012); 21 C.F.R. § 895 (2009). 
2014] cGMP Violations & the False Claims Act 45 
and fill in the details that are appropriate to a given device according to 
the current state-of-the-art manufacturing for that specific device.49 
In essence, the FDA expects device makers to employ their best 
judgment when designing state-of-the-art manufacturing processes. At 
the same time, by putting the onus on device makers to make and adhere 
to a set of standards, the FDA avoids articulating a specific set of man-
dates that could decrease the incentive for manufacturers to formulate the 
best practices possible. 
III. THE FALSE CLAIMS ACT 
A. Statutory Background of the False Claims Act 
Originally enacted during the Civil War to abate fraud against the 
government by unscrupulous contractors, the FCA “prohibits the know-
ing submission of false or fraudulent claims for payment . . . to the feder-
al government.”50 Specifically, under the FCA, any person who “know-
ingly presents, or causes to be presented, a false or fraudulent claim for 
payment or approval” or who “knowingly makes, uses, or causes to be 
made or used, a false record or statement material to a false or fraudulent 
claim . . . is liable to the United States Government.”51 Additionally, the 
FCA imposes liability on any person who “conspires to commit a viola-
tion of [any substantive section of the FCA].”52 The FCA also prohibits 
“reverse false claims,” rendering liable any person who “knowingly 
makes, uses, or causes to be made or used, a false record or statement 
material to an obligation to pay or transmit money or property to the 
[g]overnment,” or who “knowingly conceals or knowingly and improper-
ly avoids or decreases an obligation to pay or transmit money or property 
to the [g]overnment.”53 
B. Enforcement of the FCA 
Unlike the FDCA, which can be enforced by the United States ex-
clusively, the FCA may be enforced by the United States, or by a private 
person, known as a “relator,” in a qui tam action, acting on behalf of the 
                                                 
 49. See Quality System (QS) Regulation/Medical Device Good Manufacturing Practices, U.S. 
FOOD & DRUG ADMIN., http://www.fda.gov/medicaldevices/deviceregulationandguidance/ 
postmarketrequirements/qualitysystemsregulations/default.htm (last updated June 30, 2014). 
 50. United States v. Pfizer, 507 F.3d 720, 726 (1st Cir. 2007) (citing 31 U.S.C. § 3729(a)). 
 51. See 31 U.S.C. §§ 3729(a)(1)(A)–(B) (2009). 
 52. See id. § 3729(a)(1)(C). 
 53. Id. § 3729(a)(1)(G). 
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United States.54 In qui tam actions brought by relators, the United States 
has “an opportunity to evaluate the relator’s complaint and decide 
whether to assume primary responsibility for prosecuting the action.”55 If 
the United States chooses not to intervene, the relator may continue to 
pursue the action on his or her own behalf and collect a portion of any 
damages awarded.56 Under the 1986 amendment, Congress increased the 
incentives for relators to file qui tam actions and increased the penalties 
associated with FCA violations.57 By violating the FCA, defendants are 
liable for three times the government’s damages plus a civil penalty of 
$5,500–$10,000 for each false or fraudulent claim submitted to the gov-
ernment for reimbursement.58 A relator is entitled to 15%–25% of the 
recovery if the government chose to intervene or 25%–30% of the recov-
ery if the government declined to intervene.59 
Importantly, “not all fraudulent conduct gives rise to FCA liabil-
ity.”60 As one court has recognized, “[T]he statute attaches liability, not 
to the underlying fraudulent activity or to the government’s wrongful 
payment, but to the ‘claim for payment.’”61 “Evidence of an actual false 
claim is the sine qua non of a False Claims Act violation.”62 A defendant 
violates the FCA only when he has presented to the government a false 
or fraudulent claim, defined as “any request or demand . . . for money or 
property.”63 
Accordingly, the FCA is not a vehicle for policing every violation 
of a federal statute or regulation.64 Indeed, an FCA violation can be pred-
icated on a defendant’s violation of a statute or regulation only if compli-
                                                 
 54. Pfizer, 507 F.3d at 727. 
 55. Id. (citing 31 U.S.C. §§ 3730(b)(2), (b)(4), (c)(1)). 
 56. See United States ex rel. Poteet v. Bahler Med., Inc., 619 F.3d 104, 107 (1st Cir. 2010) 
(citing 31 U.S.C. § 3730(d)). 
 57. Pub. L. No. 99-562, 100 Stat. 3153 (1986).  
 58. 31 U.S.C. § 3729(a) (2009). 
 59. 31 U.S.C. § 3730(d) (2010). 
 60. United States ex rel. Karvelas v. Melrose–Wakefield Hosp., 360 F.3d 220, 225 (1st Cir. 
2004). 
 61. United States v. Rivera, 55 F.3d 703, 709 (1st Cir. 1995). 
 62. Karvelas, 360 F.3d at 225 (internal citation omitted); see also United States ex rel. Roby v. 
Boeing Co., 100 F. Supp. 2d 619, 625 (S.D. Ohio 2000) (“At a minimum, the FCA requires proof of 
an objective falsehood.”). 
 63. 31 U.S.C. § 3729(b)(2)(A) (2009); see also Karvelas, 360 F.3d at 225; United States v. 
Southland Mgmt. Corp., 326 F.3d 669, 674–75 (5th Cir. 2003) (“It is only those claims for money or 
property to which a defendant is not entitled that are ‘false’ for purposes of the False Claims Act.”). 
 64. Allison Engine Co. v. United States, 553 U.S. 662, 669 (2008) (declining to expand the 
FCA beyond its “intended role of combating fraud against the government”); United States v. Pfizer, 
507 F.3d 720, 727 (1st Cir. 2007) (“FCA liability does not attach to violations of federal law or 
regulations, such as marketing of drugs in violation of the FDCA, that are independent of any false 
claim.”). 
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ance with that statute or regulation is a condition of government pay-
ment.65 Moreover, courts have rejected FCA claims that are premised on 
expressions of opinion or professional or business judgments.66 
1. The FDA May Enforce Claims that are Factually False, Legally False 
by Express Certification, or Legally False by Implied Certification 
The DOJ may enforce claims that are factually false, legally false 
by express certification, or legally false by implied certification.67 
(a). Factually False Claims 
A claim is “factually false” when the “goods or services are either 
incorrectly described or the claim is for goods or services that were never 
provided.68 A claim cannot be considered “false” under the FCA unless it 
constitutes an objective falsehood furnished in violation of a rule, regula-
tion, contractual agreement, or standard.69 For example, a factually false 
claim would occur if a health care provider submitted a claim for reim-
bursement to Medicare for services performed when no services were 
actually performed. 
(b). Legally False Claims Under Express Certification 
Under the “express” certification theory, a claim is legally false 
“when the party making the claim for payment expressly represents 
compliance with a contract, statute, or regulation, and such compliance is 
                                                 
 65. See, e.g., United States ex rel. Steury v. Cardinal Health, Inc., 625 F.3d 262, 268 (5th Cir. 
2010) (“We have thus repeatedly upheld the dismissal of false-certification claims (implied or ex-
press) when a contractor’s compliance with federal statutes, regulations, or contract provisions was 
not a ‘condition’ or ‘prerequisite’ for payment under a contract.”); Mikes v. Straus, 274 F.3d 687, 
697 (2d Cir. 2001) (“[W]hile the [FCA] is intended to reach all types of fraud, without qualification, 
that might result in financial loss to the Government . . . it does not encompass those instances of 
regulatory noncompliance that are irrelevant to the government’s disbursement decisions.”). 
 66. See, e.g., Mann v. Heckler & Koch Defense, 630 F.3d 338, 346 (4th Cir. 2010) (“These 
sorts of [business] disagreements occur all the time, but they do not rise to the level of fraud unless 
there is a claim made on the public fisc that misrepresents the quality of a product . . . . Without such 
a misrepresentation, [plaintiff] opposed nothing more than a non-fraudulent business decision, and 
this cannot form the basis of an FCA action.” (citing United States ex rel. Owens v. First Kuwaiti 
Gen’l Trading & Contracting Co., 612 F.3d 724, 734 (4th Cir. 2010))). 
 67. In United States ex rel. Lisitza v. Johnson & Johnson, 765 F. Supp. 2d 112, 125 (D. Mass. 
2011), the court identified “three bases on which a claim may be ‘false or fraudulent’ for purposes of 
the FCA: (1) factual falsity; (2) legal falsity under an ‘express’ certification theory; and (3) legal 
falsity under an ‘implied’ certification theory.” 
 68. Mikes, 274 F.3d at 697. 
 69. See, e.g., United States v. Southland Mgmt. Corp., 326 F.3d 669, 684 (5th Cir. 2003) (en 
banc) (Jones, J., concurring). 
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a precondition to payment,” yet compliance has not occurred.70 The certi-
fication need not be in any particular form “so long as the statement of 
compliance was knowingly false when made.”71 Absent a certification of 
past compliance with a specific contract, statute or regulation, where 
such compliance is a precondition of payment, the alleged legal falsity of 
a claim for government payment must be analyzed under an implied cer-
tification theory.72 
(c). Legally False Claims Under Implied Certification 
Under the “implied” certification theory, a claim is “legally false” 
when “the claimant implies that it has complied with all of the stated 
conditions for payment.”73 Courts have held that a claim is legally false 
under an implied certification theory where a claimant makes no express 
statement about compliance with a statute or regulation, but by submit-
ting a claim for payment, implies that he or the claimant has complied 
with any contract, statute, or regulation that is a precondition to pay-
ment.74 The idea under this theory is that the government paid funds to a 
party, but the government would not have paid those funds had it known 
of the offending claimant’s violation of a law or regulation.75 The argu-
ment holds that the claim submitted for funds under the conditions de-
scribed contained an implied certification of compliance with the law or 
regulation and was, therefore, fraudulent.76 
Another way of understanding the principle of implied certification 
is that a manufacturer will be held liable under the FCA when he or she 
fails to comply with another statute for which compliance is required for 
                                                 
 70. Johnson & Johnson, 765 F. Supp. 2d at 125 (internal citation omitted); see also United 
States ex rel. Hutcheson v. Blackstone Med. Inc., 694 F. Supp. 2d 48, 62 (D. Mass. 2010) overruled 
by United States ex. rel. Susan Hutcheson & Phillip Brown v. Blackstone Med., Inc., No. 10-1505 
(1st Cir. June 1, 2001); Mikes, 274 F.3d at 698 (2d Cir. 2001) (“An expressly false claim is, as the 
term suggests, a claim that falsely certifies compliance with a particular statute, regulation or con-
tractual term, where compliance is a prerequisite to payment.”). 
 71. Johnson & Johnson, 765 F. Supp. 2d at 125 (internal citation omitted). 
 72. See United States ex rel. Kennedy v. Aventis Pharms., Inc., 610 F. Supp. 2d 938, 945–47 
(N.D. Ill. 2009); United States ex rel. Conner v. Salina Reg’l Health Ctr., Inc., 543 F.3d 1211, 1217–
18 (10th Cir. 2008). 
 73. Johnson & Johnson, 765 F. Supp. 2d at 125. 
 74. See United States ex rel. Augustine v. Century Health Servs., Inc., 289 F.3d 409, 415 (6th 
Cir. 2002). 
 75. See United States ex rel. Pogue v. Diabetes Treatment Ctrs. of Am., Inc., 238 F. Supp. 2d 
258, 264 (D.D.C. 2002). 
 76. Cf. United States ex. rel. Susan Hutcheson & Phillip Brown v. Blackstone Med., Inc., No. 
10-1505 (1st Cir. June 1, 2001) (adhering to the express language of the statute in dismissing other 
courts’ development of an implied certification theory). 
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reimbursement.77 Unlike express certification, which relies on actual 
statements of compliance, the analysis in the implied certification theory 
“focuses on the underlying contracts, statutes, or regulations themselves 
to ascertain whether they make compliance a prerequisite to the govern-
ment’s payment.”78 
2. The Materiality Requirement 
Regardless of whether a claim is construed as factually or legally 
false, courts have “long held that the FCA is subject to a judicially-
imposed requirement that the alleged false claim or statement be materi-
al.”79 A false statement is material if it has “a natural tendency to influ-
ence, or [is] capable of influencing, the payment or receipt of money or 
property.”80 Materiality involves a “determination of the weight that the 
decision-maker would have given particular information.”81 
Liability is not typically found under the FCA unless plaintiffs can 
prove: (1) the false statement or claim was essential to the government’s 
funding decision; (2) the government specifically relied on the falsity; 
and (3) the falsity caused the government to pay out sums it would not 
have otherwise paid.82 For example, in United States ex rel. Sanders v. 
North American Bus Industries, Inc.,83 the court held that the relator’s 
allegations that a false claim for payment had been made focused on de-
tails that were unimportant to the government’s decision to pay or not to 
                                                 
 77. See In re Pharma. Indus. Average Wholesale Price Litig., 491 F. Supp. 2d 12, 18 (D. Mass. 
2007) (holding that hospitals submitted legally false claims under an implied certification theory for 
Medicaid reimbursement when they failed to comply with the anti-kickback statute (“AKS”) because 
Medicare requires compliance with the AKS). 
 78. United States ex rel. Conner v. Salina Reg’l. Health Ctr., 543 F.3d 1211, 1218 (10th Cir. 
2008) (emphasis added); see also United States v. Science Apps. Int’l, 626 F.3d 1257, 1269 (D.C. 
Cir. 2010) (“[W]e hold that to establish the existence of a ‘false or fraudulent’ claim on the basis of 
implied certification of a contractual condition, the FCA plaintiff—here the government—must 
show that the contractor withheld information about its noncompliance with material contractual 
requirements.”). 
 79. United States ex rel. Loughren v. Unum Grp., 613 F.3d 300, 307 (1st Cir. 2010). 
 80. 31 U.S.C. § 3729(b)(4) (2009). Prior to the FERA amendments, the United States Supreme 
Court decided in Allison Engine Co. v. United States ex rel. Sanders, 553 U.S. 662, 668–69 (2008), 
that liability for false statements supporting false claims was limited to fraudulent statements de-
signed “to get” false claims paid or approved “by the [g]overnment.” Id. FERA’s materiality re-
quirement replaced Allison Engine’s intent requirement and incorporated the materiality standard 
already applied by numerous courts in FCA cases. JOHN T. BOESE, CIVIL FALSE CLAIMS & QUI TAM 
ACTIONS 1-75, 7-77 (3d ed. 2010). Therefore, “FERA’s explicit inclusion of this requirement in 
Sections 3729(a)(1)(B) and (G) should not affect the ultimate outcome in [FCA] cases.” Id. at 1-78. 
Plaintiffs’ allegations fail under both the pre-FERA and post-FERA requirements of the FCA. 
 81. Unum Grp., 613 F.3d at 308. 
 82. BOESE, supra note 81, at 2-166. 
 83. United States ex rel. Sanders v. N. Am. Bus Indus., Inc., 546 F.3d 288 (4th Cir. 2008). 
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pay, and fell well short of what would be required to satisfy a materiality 
standard. 
3. The Causation Requirement 
After a reviewing court determines that a false statement was made 
and that the falsity was material to the government’s decision to pay, the 
courts apply principles of tort law to the False Claims Act to see if causa-
tion exists. Indeed, “[T]he FCA does not provide a special definition for 
causation, and neither the Supreme Court nor any Circuit Court of Ap-
peals has grafted such a special definition on the FCA. Absent an FCA-
specific definition of causation, the court will apply common-law tort 
causation concepts.”84 Most courts have adopted a proximate cause ap-
proach to FCA violations as opposed to a “but for” analysis.85 That is, a 
person will be liable for all normal consequences of that person’s con-
duct unless the intervening event in the causal chain is unforeseeable.86 
IV. USING THE FCA TO ENFORCE THE FDCA 
Given the statutory background of cGMPs and QSRs, the enforce-
ment mechanisms available to the FDA, and the subject matter expertise 
the Agency can draw upon, it follows that non-fraudulent cGMP viola-
tions should be enforced by the FDA under mechanisms afforded to the 
agency. No private right of action exists for FDCA enforcement. On the 
other hand, fraudulent and felonious violations of cGMPs should be en-
forced by the DOJ or relators on behalf of the United States, which have 
the resources and the expertise to investigate and prosecute such viola-
tions either via federal prosecutors or the relator’s private counsel. The 
existence of fraudulent and felonious behavior is the trigger for DOJ in-
volvement in the context of cGMP violations, not the per se existence of 
an underlying violation. 
                                                 
 84. United States ex rel. Franklin v. Parke–Davis, No. Civ.A. 96–11651PBS, 2003 WL 
22048255 at *4 (D. Mass. Aug. 22, 2003). 
 85. See, e.g., United States v. Hibbs, 568 F.2d 347, 349–51 (3d Cir. 1977) (holding that the 
“but for” causation element would not be applied, but rather a causal connection should be utilized 
when assessing a false claim allegation); see also United States ex rel. Schwedt v. Planning Research 
Corp., 59 F.3d 196 (D.C. Cir. 1995). 
 86. See United States ex rel. Sikkenga v. Regence Blue Cross Blue Shield, 472 F.3d 702, 714 
(10th Cir. 2006) (noting that “[s]uch an approach is useful in analysing causation under § 3729 as 
well, and provides a familiar test—that of proximate causation—to determine whether there is a 
sufficient nexus between the conduct of the party and the ultimate presentation of the false claim to 
support liability under the FCA”); see also United States ex rel. Baker v. Cmty. Health Sys., 709 F. 
Supp. 2d 1084 (D.N.M. 2010). 
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A. Implied Private Right of Action: Is There a Right? 
Under the FDCA, there is no express private right of action allow-
ing a citizen to bring an action for a violation of the Act. Moreover, it is 
unlikely that any court would imply a private right of action under the 
FDCA. Since the mid-1970s, the Supreme Court has incrementally re-
stricted the ability of courts to imply a private right of action under fed-
eral statutes.87 
For example, in Cort v. Ash, a stockholder brought a civil action for 
relief under a criminal statute prohibiting corporations from making con-
tributions or expenditures in connection with any presidential election 
where no private violation or remedy was articulated in the statute.88 
When the company advertised in a way that was potentially impermissi-
ble under the statute, the Court determined that no private right of action 
was implied.89 Moreover, in Cort, the Court articulated a four-factor test 
for determining if a statute warrants a private right of action: (1) whether 
the plaintiff is “one of the class for whose especial benefit the statute was 
enacted”; (2) whether there is evidence of explicit or implicit legislative 
intent to create a remedy; (3) whether implying a right of action would 
be “consistent with the underlying purposes of the legislative scheme”; 
and (4) whether the cause of action is one “traditionally relegated to state 
law . . . so that it would be inappropriate to infer a right of action based 
solely on federal law.”90 
Over the next several years, the Supreme Court narrowed the origi-
nal four-factor test. In Touche Ross & Co.91—a liquidated assets action 
brought under § 17(a) of the Securities Exchange Act—the Court articu-
lated three factors for determining whether a private right of action is 
permissible under a statute. These factors include determining whether 
the “language and focus of the statute, its legislative history, and its pur-
pose” confer a private right of action.92 Nonetheless, the Court opined, 
the “central inquiry remains whether Congress intended to create, either 
expressly or by implication, a private cause of action.”93 
                                                 
 87. Louis Ebinger, Sarbanes-Oxley Section 510(A): No Implied Private Right of Action, and a 
Call to Congress for an Express Private Right of Action to Enhance Analyst Disclosure, 93 IOWA L. 
REV. 1919, 1930, 1934 (2008). 
 88. Cort v. Ash, 422 U.S. 66, 70–75 (1975). 
 89. Id. 
 90. Id. at 78. 
 91. Touche Ross & Co. v. Redington, 442 U.S. 560, 575 (1978). 
 92. Id. at 575–76. 
 93. Id. at 575; see also Santa Clara Pueblo v. Martinez, 436 U.S. 49, 64 (1978) (noting that 
implying a right where a statute is silent as to the right is impermissible when stating that “implying 
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When the Court in Alexander v. Sandoval94 held that the discrimi-
natory impact provision of Title VI of the Civil Rights Act of 1964 did 
not contain an implied private right of action, the Court determined that 
congressional intent is the sole criterion for determining whether a statute 
confers a private right of action. The court opined, “Without [statutory 
intent], a [right] of action does not exist and courts may not create one, 
no matter how desirable that might be as a policy matter, or how compat-
ible with the statute.”95 More recently, in Stoneridge Investment Partners 
v. Scientific–Atlanta, Inc., the Court refused to expand an existing im-
plied private right of action in the context of securities litigation when 
the Court determined that § 10(b) of the Securities Exchange Act and 
SEC Rule 10b-5 did not imply a private right of action.96 
What is clear from the case law on this point is that one dispositive 
question exists when inquiring whether a statute confers a private right of 
action; namely, “whether Congress intended to create, either expressly or 
by implication, a private cause of action.”97 As applied to the FDCA, it 
seems unlikely that any reviewing court would imply a right for a private 
citizen to bring an action against a corporation for violating the cGMP 
because such actions are uniquely reserved for the FDA. The multifacet-
ed arsenal at the disposal of the FDA makes the agency uniquely posi-
tioned to enforce its governing statute in ways that a private citizen is 
not. Moreover, only the FDA is statutorily empowered to determine 
when a cGMP violation has occurred in the first instance, which cabins 
enforcement even further away from private litigants. Nonetheless, re-
cent case law suggests that private litigants may make an end-run around 
the prohibition against implying a private right of action under the FDCA 
by invoking the FCA. 
1. Without the Right to Invoke the FDCA, Litigants Invoke the FCA 
Following the announcement of GSK’s $750 million settlement 
with the United States Attorney’s Office (USAO) for the District of Mas-
sachusetts for allegedly releasing adulterated drugs into the stream of 
commerce due to cGMP violations, whether the FCA may be used by 
private citizens to enforce cGMP violations,98 QSR violations, or both 
                                                                                                             
a private right of action on the basis of congressional silence is a hazardous enterprise, at best”); 
Cent. Bank of Denver v. First Interstate Bank of Denver, 511 U.S. 164, 174–76 (1994). 
 94. Alexander v. Sandoval, 532 U.S. 275, 287 (2001). 
 95. Id. at 286–87. 
 96. See Stoneridge Inv. Partners v. Scientific–Atlanta, Inc., 552 U.S. 148, 161–62 (2008). 
 97. Touche Ross & Co. v. Redington, 442 U.S. 560, 575 (1978). 
 98. GSK Settlement Agreement, supra note 3. 
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under the FDCA became an open question. Following the GSK settle-
ment, in United States v. McNeil–PPC, Inc., the McNeil–PPC Inc. 
(McNeil) division of Johnson & Johnson entered into a consent decree of 
permanent injunction with the federal government for manufacturing 
violations at three plants that resulted in several over-the-counter prod-
ucts being recalled and one plant being shut down.99 The federal gov-
ernment alleged that McNeil and two employees violated the FDCA by 
placing adulterated drugs into interstate commerce and causing drugs 
held for sale to become adulterated.100 Notably, the consent decree spe-
cifically stipulates that entry of the decree does not foreclose claims aris-
ing under the FCA. Thus, the consent decree held open the possibility 
that a private citizen could bring a claim against the party even though a 
partial resolution was reached. 
The concept that a relator may bring a cGMP claim under the FCA 
is not new. In October 2004, the National Conference for Relators’ 
Counsel hosted a panel discussion entitled, “The Federal Food, Drug and 
Cosmetic Act and Its Application to Qui Tam: Pharmaceutical and Medi-
cal Device Cases.” During the same year, the panel’s moderator pub-
lished an article, cGMP Violations May Be the Basis for Qui Tam Law-
suits in the United States.101 In United States ex rel. Paul G. King v. Al-
con Laboratories, Inc., despite being dismissed for failure to plead with 
the requisite particularity under FRCP 9(b), the relator claimed that de-
fendants violated sections 3729(a)(1) and (a)(2) of the FCA by knowing-
ly and intentionally choosing to operate in a manner that did not comply 
with the FDA’s cGMP.102 
To protect against interference with the FDA’s exercise of this dis-
cretion, Congress prohibited “private litigants” from “fil[ing] suits for 
noncompliance with the medical device provisions” of the FDCA.103 As 
stated by the Court in Buckman Co. v. Plaintiffs’ Legal Committee, the 
FDA’s “flexibility” in deciding whether and how to enforce the FDCA 
“is a critical component of the statutory and regulatory framework under 
which the FDA pursues difficult (and often competing) objectives.”104 
                                                 
 99. United States v. McNeil–PPC, Inc., No. 11-1745 (E.D. Pa. Mar. 10, 2011). 
 100. Id. 
 101. See Kenneth Nolan, CGMP Violations May Be the Basis for Qui Tam Lawsuits in the 
United States, 8 QUAL. ASSUR. J. 167 (2004). 
 102. United States ex rel. Paul G. King v. Alcon Labs., Inc., 232 F.R.D. 568, 569 (N.D. Tex. 
2005). 
 103. Buckman Co. v. Plaintiffs’ Legal Comm., 531 U.S. 341, 349 n.4 (2001) (citing 21 U.S.C. 
§ 337(a)). 
 104. Id. at 349. 
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In In re Medtronic, Inc.,105 for example, a group of plaintiffs assert-
ed manufacturing defect claims against Medtronic premised on alleged 
failures to adhere to particular internal quality protocols used in welding 
leads. The Minnesota federal district court rejected plaintiffs’ argument, 
noting that the FDCA regulations are “simply too generic, standing 
alone, to serve as the basis for Plaintiff’s manufacturing-defect 
claims.”106 The court continued: 
Plaintiffs allege that Medtronic’s welding techniques were “defec-
tive,” but they have not pleaded how that welding technique violat-
ed the CGMPs or QSR. This is likely because the CGMPs and QSR 
do not provide such a fine level of detail concerning the manufac-
ture of defibrillator leads (or most other medical devices). . . . Plain-
tiffs simply have not identified any specific requirements in the 
CGMPs/QSR that were purportedly violated by Medtronic. Without 
any such specified requirement, Plaintiffs necessarily seek to im-
pose requirements that differ from the CGMPs/QSR.107 
What is clear from the statute is that only the United States via the 
FDA has statutory authority to enforce the cGMP and/or QSR violations 
under the FDCA:108 “The FDCA leaves no doubt that it is the Federal 
Government rather than private litigants [that is] authorized to file suit 
for noncompliance with the medical device provisions in the FDCA.”109 
2. FCA’s Remedial Scheme Applied to an FDCA Violation 
The remedial schemes flowing from a violation of the FCA and the 
FDCA differ, suggesting that there is a different level of culpability ac-
corded to violating one statute or the other. Liability under the FCA may 
include treble damages, whereas liability for FDCA violations may result 
in disgorgement of profits. As discussed above, if the FCA is violated, 
defendants are liable for three times the government’s damages (treble 
damages) plus a civil penalty of $5,500–$10,000 for each false or fraudu-
lent claim submitted.110 A relator is entitled to a 15%–25% share of the 
                                                 
 105. In re Medtronic, Inc. Sprint Fidelis Leads Prods. Liab. Litig., 592 F. Supp. 2d 1147, 1157 
(D. Minn. 2009). 
 106. Id. 
 107. Id. at 1158. 
 108. Id. at 1161 (referring to 21 U.S.C. § 337(a)); see also United States v. Utah Med. Prods., 
Inc., 404 F. Supp. 2d 1315, 1317 (D. Utah 2005) (denying injunctive action brought by the United 
States on behalf of the FDA against a medical device manufacturer for alleged violations of the 
QSR). 
 109. In re Medtronic, Inc., 592 F. Supp. 2d at 1161 (quoting Buckman Co. v. Plaintiffs’ Legal 
Comm., 531 U.S. 341, 349 n.4 (2001)). 
 110. 31 U.S.C. § 3729(a) (2009). 
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recovery if the government chooses to intervene or 25%–30% of the re-
covery if the government declines to intervene.111 
In Vermont Agency of Natural Resources v. United States ex rel. 
Stevens, the Supreme Court, breaking with its historical understanding of 
FCA damages as remedial, labeled the Act’s treble damages as “puni-
tive.”112 As was noted in Texas Industries, Inc. v. Radcliff Materials, Inc., 
“[t]he very idea of treble damages reveals an intent to punish past, and to 
deter future, unlawful conduct, not to ameliorate the liability of wrong-
doers.”113 Courts have allowed the FDA to impose disgorgement of prof-
its as part of the government’s relief in actions arising from violations 
under the FDCA.114 While treble damages and disgorgement of profits 
may both be considered punitive in nature in the contexts discussed here-
in, disgorgement of profits is a far cry from treble damages. Moreover, 
had Congress intended for cGMP violations to be met with treble dam-
ages, such a remedial structure could have been legislated; however, it 
was not. Given the flexible nature of the FDCA as applied to cGMP and 
the lack of legislation regarding treble damages, such harsh treatment is 
arguably unwarranted and inappropriate in the context of cGMP viola-
tions. It is hard to imagine the imposition of treble damages for cGMP 
violations resulting from a lack of shared understanding about the precise 
and current nature of the requirements, or from a genuine good faith dis-
agreement about technical requirements; these are not “egregious behav-
ior(s)” deserving of such an extraordinary remedy.115 
3. cGMP Violations After Rostholder 
In United States ex rel. Rostholder, the reviewing court held that 
noncompliance with cGMPs will not give rise to an FCA violation be-
cause compliance with the cGMPs is not required for payment by Medi-
care and Medicaid.116 In the Statement of Interest117 filed in connection 
with the Rostholder proceedings, the government framed the issue of 
whether a cGMP violation may give rise to an FCA claim in terms of 
                                                 
 111. 31 U.S.C. § 3730(d) (2010). 
 112. Vt. Agency of Natural Res. v. United States ex rel. Stevens, 529 U.S. 765, 784–86 (2000). 
 113. Texas Indus., Inc. v. Radcliff Materials, Inc., 451 U.S. 630, 639 (1981). 
 114. See, e.g., United States v. RxDepot Inc., No. 05-5003 (10th Cir. 2006); United States v. 
Lane Labs-USA Inc., 427 F.3d 219 (3d Cir. 2005); United States v. Universal Mgmt. Servs. Inc., 
191 F.3d 750 (6th Cir. 1999). 
 115. See King & Walsh, supra note 19, at 167. 
 116. United States ex rel. Rostholder v. Omnicare, Inc., 745 F.3d 694, 701 (4th Cir. 2014). 
 117. A Statement of Interest is a formal filing made to a reviewing court by the United States 
when the United States is not a party to an action but has a vested interest in the outcome of the case. 
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whether or not the deficiencies involved would impact the government’s 
decision to pay a claim for a given drug.118 
(a). The Rostholder Holding’s Implications for cGMP Violations 
Proceedings to enforce or restrain violations of the FDCA must be 
brought by the FDA because only the FDA is statutorily empowered to 
determine whether a cGMP violation has occurred in the first instance.119 
As such, private plaintiffs should not be able to use the FCA to make an 
end-run around the jurisdictional limitations of the FDCA and pursue 
alleged violations of the FDCA under the guise of an FCA suit.120 In 
Rostholder, the court made a more global comment regarding the appro-
priateness of using the FCA to enforce cGMP violations when the court 
noted, “When an agency has broad powers to enforce its own regula-
tions, as the FDA does in this case, allowing FCA liability based on 
regulatory non-compliance could ‘short-circuit the very remedial process 
the Government has established to address non-compliance with those 
regulations.’”121 Because private citizens have no private cause of action 
under the FDCA to challenge alleged FDCA violations, any efforts to use 
the FCA as a “back door” to private FDCA enforcement should be 
preempted by the FDCA. 
Not only did the Rostholder court identify the statutory argument 
for limiting the use of the FCA to enforce cGMP violations, the court 
also noted that noncompliance with cGMPs will not give rise to an FCA 
violation because compliance with the cGMPs is not required for pay-
ment by Medicare and Medicaid. Therefore, noncompliance with a 
cGMP is not sufficient to constitute a false statement as contemplated by 
the FCA.122 What is required for a drug to be covered or for payment to 
issue from Medicare and Medicaid is that a drug be approved for safety 
and effectiveness under the FDCA.123 
                                                 
 118.  United States’ Statement of Interest As to Defendants’ Motion to Dismiss at 3–4, United 
States ex rel. Rostholder v. Omnicare, Inc., 745 F.3d 694 (4th Cir. 2014) (No. CCB-07-1283), 2011 
WL 10857612 [hereinafter U.S. Statement of Interest]. 
 119. See 21 U.S.C. § 337(a) (2014); see also United States v. Utah Med. Prods., Inc., 404 F. 
Supp. 2d 1315, 1317 (D. Utah 2005). 
 120. See In re Epogen & Aranesp Off-Label Mktg. & Sales Practices Litig., 590 F. Supp. 2d 
1282, 1290 (C.D. Cal. 2008) (rejecting plaintiffs’ attempt “to use RICO as a vehicle to enforce the 
FDCA and the regulations promulgated thereunder”). 
 121. United States ex rel. Rostholder v. Omnicare, Inc., 745 F.3d 694, 702 (4th Cir. 2014) 
(quoting United States ex rel. Wilkins v. United Health Grp., Inc., 659 F.3d 295, 310 (3d Cir. 2011)). 
 122. Id. at 701–02. 
 123. Id. See also 21 U.S.C. § 355 (2013); 42 U.S.C. § 1396r-8(k)(2)(A)(i) (2014) (Medicaid); 
42 U.S.C. § 1395w-102(e) (2014) (Medicare Part D); 42 C.F.R. § 423.100 (2013) (defining Medi-
care Part D drug). 
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(b). The Government’s Statement of Interest in Rostholder Links cGMP 
Violations with FCA Claims to the Government’s Decision to Pay Claims 
for Products 
In its Statement of Interest, the government frames the issue of 
whether a cGMP violation may give rise to an FCA claim in terms of 
whether or not the deficiencies involved would impact the government’s 
decision to pay a claim for a given drug.124 The government concludes 
that “cGMP regulations may, in certain circumstances, be material to the 
government’s decision whether to pay for the affected products.”125 The-
se circumstances include “violations of cGMP regulations . . . where the 
violations are significant, substantial, and give rise to actual discrepan-
cies in the composition or functioning of the product.”126 The govern-
ment goes on to argue that some drugs may be so affected by the cGMP 
violations that the drug is essentially worthless and, therefore, ineligible 
for payment by the government.127 
According to the court in Rostholder, whether a false claim exists 
or not depends on whether compliance with the underlying regulation is 
a precondition of payment.128 In contrast, in its Statement of Interest, the 
government is focused on the fact that certain deficiencies in a drug 
would materially impact the government’s decision to pay for the drug, 
and suggests that compliance with a regulation could in fact, in certain 
situations, be a precondition of payment.129 
The Rostholder court’s theory of liability and the government’s 
concern about reimbursement in certain situations where a drug is defi-
cient can be read together, rather than at odds. It is not that noncompli-
ance with a regulation gives rise to an FCA violation per se; rather, non-
compliance with a regulation may, if coupled with fraudulent behavior, 
give rise to an FCA violation. It is the fraud that is the hook for the 
claim, not the violation of the regulation, even though fraud may be 
committed in the context of noncompliance with a regulation. In other 
words, fraud may be the basis for a cGMP violation, and then, and only 
then, would an FCA claim be triggered. 
                                                 
 124. U.S. Statement of Interest, supra note 119, at 3–4. 
 125. Id. 
 126. Id. 
 127. Id.; see, e.g., Chesbrough v. VPA, P.C., 655 F.3d 461, 468 (6th Cir. 2011). 
 128. United States ex rel. Rostholder v. Omnicare, Inc., 745 F.3d 694, 701–02 (4th Cir. 2014). 
 129. U.S. Statement of Interest, supra note 119, at 4. 
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(c). DOJ Interventions in cGMP Violation Cases Occur Under Egregious 
and Fraudulent Circumstances 
Under the Rostholder court’s theory of liability, the DOJ or a rela-
tor could have a cognizable FCA claim if the FDA would have with-
drawn its approval of a drug or device had it been in a position to make 
such a determination but could not due to fraudulent representations 
made to the FDA. Whether a drug or device is properly approved as safe 
and effective may be called into question if fraudulent representations are 
made to the FDA resulting in drugs and devices being released into the 
market that are so unsafe and so ineffective that the FDA would have 
withdrawn approval but for the fraudulent representations made to the 
agency. In this scenario, submitting a claim for reimbursement for drugs 
or devices that are defective to the point that the FDA would have with-
drawn its approval of the drug or device is arguably a false claim and, 
therefore, appropriately subject to FCA allegations even under 
Rostholder. In fact, this is sound jurisprudence and sound policy being 
born out in practice. A small sampling of the existing body of cGMP 
case law demonstrates that the FCA is successfully invoked in exactly 
these kinds of scenarios. The DOJ has intervened and relators have only 
recovered under the FCA in the most egregious cGMP violation cases 
and in cases where there exists clear fraud on the FDA. 
In United States ex rel. Cheryl Eckard v. GlaxoSmithKline, GSK 
was accused of knowingly selling contaminated drugs made at its manu-
facturing facility in Puerto Rico from 2001–2005.130 GSK’s plant was 
alleged to have used a water system infected with microbial contamina-
tion, resulting in products being made under unsterile conditions.131 The 
plant undertook production and bottling of tablets of varying strength or 
lacking therapeutic effect wholesale, and the plant had a history of prod-
uct mix-ups resulting in commingling of drug products.132 Additionally, 
the plant failed to report important safety data to the FDA.133 The cGMP 
violations involved rose to the level of criminal prosecution, albeit de-
clined via a Side Letter Agreement in exchange for full performance of 
the Plea Agreement.134 
More recently, in United States v. Ranbaxy Laboratories, Ltd., 
Ranbaxy settled criminal and civil allegations that the generic manufac-
turer knowingly introduced drugs produced from a facility with 
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longstanding cGMP failures into interstate commerce.135 Specifically, 
Ranbaxy was cited for having incomplete testing records, an inadequate 
stability testing program, failing to disclose relevant information to the 
FDA during inspection, failing to maintain sterile manufacturing condi-
tions, and failing to file timely field alerts (a required FDA submission 
upon a manufacturer discovering a drug product poses safety threats).136 
In both the GlaxoSmithKline case and the Ranbaxy case, one may 
safely conclude that the FDA—were it properly informed of the defi-
ciencies at stake—would have withdrawn approval of the adulterated 
drugs under 21 U.S.C. § 355, which would have rendered the drugs inel-
igible for payment under the Medicare and Medicaid statutes.137 The 
same conclusion cannot be drawn from the underlying facts in 
Rostholder.138 
In Rostholder, the relator alleged that Omnicare packaged both pen-
icillin and non-penicillin products in the same building without comply-
ing with the cGMP, which required separation and controls be in place to 
prevent cross-contamination.139 The cGMP violation led the FDA to is-
sue a warning letter, and the company purportedly disposed of $19 mil-
lion dollars of pharmaceutical inventory.140 
B. The FDA Should Have Oversight over Garden Variety cGMP Viola-
tions; DOJ over cGMP Violations of a Fraudulent Nature 
When contrasting the underlying facts in Rostholder to Glax-
oSmithKline and Ranbaxy, it becomes clear that the violations at stake 
are of a very different nature. In Rostholder, the cGMP violations includ-
ed what are colloquially understood as garden-variety cGMP violations, 
and the conditions underlying the violations were not based in fraud or 
false statements. Thus, the FDA was perfectly positioned to identify and 
act on the violations. In fact, the FDA was able to investigate and reme-
diate the issue within two visits to the site.141 The FDA’s ameliorative 
actions indicate that the cGMP violation involved did not rise to the level 
of the FDA needing to withdraw approval of the drugs, regardless of 
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whether the drug was adulterated within the meaning of FDCA.142 In sit-
uations resembling Rostholder, the FDA is the appropriate arm of the 
government to address the regulatory violations. 
What distinguishes GlaxoSmithKline and Ranbaxy from Rostholder 
is the fraudulent conduct at issue and the consequences of that conduct. 
If there is a place for the DOJ and relators to initiate actions to enforce 
the FDCA using the FCA, the actions should be restricted to cases where 
there either exists some evidence of criminal intent to defraud the FDA, 
significant and reckless disregard for the truth of statements made to 
FDA, or systemic, pervasive, and long-standing cGMP failures where a 
real threat to patient harm exists. In such instances, companies have en-
gaged in felonious FDCA adulteration, and the DOJ has the requisite 
experience and resources to adequately investigate and prosecute such 
companies. The government’s Statement of Interest admits: 
The United States readily acknowledges that not every violation of 
the Food Drug & Cosmetic Act is a per se violation of the FCA be-
cause not every regulatory violation has a nexus to payment. Rather, 
where the defendant has engaged in a fraudulent course of conduct 
involving such violations, the touchstone is whether the defendant’s 
conduct compromised “the reliability and trustworthiness of a 
claim” such that it might cause the government to actually refuse 
payment.143 
In other words, the issue at stake in a cGMP violation case that im-
plicates the FCA is not the underlying cGMP violation per se, but rather 
the fraudulent conduct giving rise to an egregious cGMP violation such 
that, were the facts known to the FDA, the drug or device would have 
been withdrawn from the marketplace because the egregiousness of the 
violation indicates that the drug was either unsafe or ineffective. In either 
case, the claim for payment would have been denied. 
This analysis is bolstered in light of the 2013 DOJ announcement 
that it would be increasing enforcement against pharmaceutical manufac-
turers by examining violations of cGMPs that create an unacceptable risk 
of harm to consumers and the public.144 The DOJ’s interest appears to be 
in felonious cGMP violations that the FDA cannot manage on its own 
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due to the underlying fraudulent behavior on the part of the manufactur-
er. 
V. CONCLUSION 
In instances where companies have engaged in felonious FDCA 
adulteration, the DOJ has the requisite experience and resources to ade-
quately investigate and prosecute such violations. In these cases, the DOJ 
can rely on the FDA’s subject matter expertise for guidance regarding 
cGMP violations. Enforcement of egregious and felonious cGMP viola-
tions by the FDA would require significant time and resources from the 
agency and, in the end, would still require relying upon the DOJ for 
prosecution. Moreover, it is not clear that the FDA would have access to 
information that could uncover such fraudulent behavior, whereas rela-
tors would have access to such information. Thus, the DOJ and the FDA 
perforce must work hand in hand when enforcing the FDCA via the 
FCA. That said, the DOJ should not initiate cGMP violation actions in 
the absence of fraud and without input from the FDA. Were the DOJ to 
take up garden-variety cGMP violations, the DOJ would essentially be 
acting as the FDA, which would be unfortunate given the DOJ’s lack of 
subject matter expertise. It is in everyone’s best interest to have cGMP 
violations defined and enforced by the agency with the best information 
in the field; namely, the FDA. 
 
